GenEmbryomics appoints Tess Burleson as an independent director in preparation for US national exchange listing.

GenEmbryomics, a medical genetics company, appoints Tess Burleson as an independent director in preparation for US national exchange listing. The move reflects the company's commitment to global expansion and enhanced corporate governance standards. Burleson brings expertise in healthcare, biotechnology, and strategic business development to strengthen GenEmbryomics' board.